#BioelectronicMedicine; The Future for Medicine:
(NASDAQ: $BSGM) (NASDAQ: $NVTR) (NYSE: $BSX) (NASDAQ: $IRTC)
Point Roberts, WA and Delta, BC - February 22, 2019
(Investorideas.com Newswire) Investorideas.com, a leading investor news
resource covering medical technology and healthcare stocks releases a snapshot
looking at the rapid advancements happening in the med tech sector and how many
of these "far off" projects are now on the verge of reality.
According to IDTechEx “The market for bioelectronic medicine will exceed $60 billion by 2029.”
They explain Bioelectronic medicine, or electroceuticals, is
the use of electrical stimulation to treat diseases of the human body in ways
that current pharmaceutical interventions cannot.
BioSig Technologies,
Inc. (NASDAQ: BSGM), a medical device company developing a
proprietary biomedical signal processing platform designed to address an unmet
technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the
first patient cases using PURE EP™ System, its FDA approved proprietary signal
acquisition and processing technology. The first commercial use of the System
was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.
Read this in full at https://www.investorideas.com/news/2019/biotech/02221Stocks-BioelectronicMedicine.asp
“With the use of the PURE EP™ System, I was able to identify cardiac
signals which were previously undetectable to me. I believe that the PURE EP™ System
could change diagnostic and treatment strategies of arrhythmias, leading to
more successful outcomes,” commented Dr. Andrea Natale, who conducted the
studies.
The PURE EP™ System
was used during standard studies on patients with persistent atrial fibrillation
and conducted in parallel with Abbott’s EnSite Precision™ and Biosense
Webster’s (Johnson & Johnson) CARTO™ cardiac mapping systems. The goal of
the first commercial use of the technology was aimed at validating the System’s
key value proposition elements and report on the overall user experience during
the procedure.
Kenneth L. Londoner,
Chairman and CEO of BioSig Technologies stated, “We are well positioned to
deliver on our strategic goals for 2019 and look forward to the expansion of
our evaluation efforts in the coming months.”
The BioSig
Technologies system will sell for $250,000 each, in addition to a $100,000
software license.
Nuvectra Corporation
(NASDAQ: NVTR), a medical device company dedicated to
neuromodulation, recently announced that the US Food and Drug Administration
(FDA) has advised that its review of the Company’s pre-market approval (PMA)
application for its Virtis Sacral Neuromodulation (SNM) system has been
extended beyond the expiration of the FDA’s 180-day review period.
This small delay for
the company will most likely be overshadowed by the release of its financial results for the fourth
quarter and full year ended December 31, 2018 on Thursday, February 28, 2019
after market close.
Boston Scientific Corporation (NYSE: BSX) has reported their results for Q4 and the full year of 2018, in which
they generated sales of $2.561 billion during Q4, representing growth of
6.3 percent on a reported basis, 8.2 percent on an operational basis and 7.0
percent on an organic basis, all compared to the prior year period.
For the full year
2018, the company generated sales of $9.823 billion, which represents growth of
8.6 percent on a reported basis, 8.0 percent on an operational basis and 7.2
percent on an organic basis, all compared to the prior year period.
Commenting on their
earnings, Chairman and CEO Mike Mahoney said, "Meaningful innovation and
focused execution helped us deliver strong financial results in 2018. We remain
driven by the opportunity to help more patients with our life-changing
technologies, including a robust long-term pipeline of new devices and
therapies."
iRhythm Technologies,
Inc. (NASDAQ: IRTC) technology combines wearable biosensor devices
worn for up to 14 days and cloud-based data analytics with powerful proprietary
algorithms that distill data from millions of heartbeats into clinically
actionable information. The company believes improvements in arrhythmia detection and
characterization have the potential to change clinical management of patients.
Companies with
innovative products now being approved, tested, and brought to market are not
only showing great financial growth for their shareholders but are also changing
lives and adding new depths to the medical community. These innovations in
medical technology are showing us that the future of healthcare is already
here.
About Investorideas.com
Investorideas.com is a recognized news source
publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about
cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water,
renewable energy and more . Investorideas.com original branded content includes
the daily Crypto
Corner and Podcast, Play by Play sports and
stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI Eye Podcast and column
covering developments in AI.
Social Media
Disclaimer/Disclosure:
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Contact each company
directly regarding content and press release questions. Disclosure is posted
for each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this news article featuring
BioSig Technologies is a paid for service on Investorideas.com (third party). Learn more about costs and our
services https://www.investorideas.com/News-Upload/
Contact Investorideas.com
800-665-0411
